Harmony Biosciences Holdings inc (HRMY) - News Archive

Showing 2 of 2 results.

Harmony Biosciences Cuts Through Challenges with Robust Q3 2025 Results and Strategic Advances

: Harmony Biosciences Holdings, Inc. has announced a strong performance for the third quarter of 2025, primarily propelled by its flagship drug, WAKIX (pitolisant). This article outlines the key developments contributin...

Oct 23, 2025 • Major Pharmaceutical Preparations Industry Business Update Nasdaq

Harmony Biosciences Reports Robust Growth with WAKIX as Stock Struggles Short-Term

In the recently released press statement, Harmony Biosciences Holdings Inc reported impressive financial results for the third quarter of 2023. The company s flagship product, WAKIX (pitolisant), achieved a net revenue...

Oct 31, 2023 Dividend